Caption Management’s Karyopharm Therapeutics KPTI Stock Holding History

Caption Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.05M	Buy	+1,086,900	New	+$8.29M	0.04%	479
2021 Q3	–	Sell	-5,333	Closed	-$826K	–	1649
2021 Q2	$826K	Buy	+5,333	New	+$774K	0.01%	944
2020 Q2	–	Sell	-6,000	Closed	-$1.73M	–	1084
2020 Q1	$1.73M	Buy	6,000 +2,333	+64%	+$644K	0.1%	288
2019 Q4	$1.05M	Buy	3,667 +2,667	+267%	+$579K	0.04%	498
2019 Q3	$144K	Sell	1,000 -5,667	-85%	-$768K	0.01%	616
2019 Q2	$599K	Buy	+6,667	New	+$535K	0.03%	455

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Caption Management's KPTI Position: Q3 2020 in Review

Caption Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 1,332 shares — an estimated $379K sold.

Caption Management first reported a position in KPTI in Q2 2019 and held it in 2 quarters. The position peaked at $379K in Q2 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

Caption Management reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
Caption Management sold 1,332 Karyopharm Therapeutics shares in Q3 2020, an estimated $379K.
Caption Management first reported a position in Karyopharm Therapeutics in Q2 2019 and held it in 2 quarters.
Caption Management's Karyopharm Therapeutics position peaked at $379K in Q2 2020.
157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Caption Management's 13F filing for Q3 2020, filed 16 Nov 2020.